Investment Thesis — STERIS plc
The market underestimates STERIS's ability to leverage regulatory-driven demand for infection prevention, especially as hospital capex rebounds post-pandemic. Investors are anchored to recent flat returns and overlook the compounding effect of new sterilization mandates and aging infrastructure. This sets up a scenario where growth reaccelerates just as sentiment bottoms.
Catalysts
- Acceleration of hospital capex as regulatory deadlines near
- New infection control mandates or reimbursement incentives
- Earnings surprise from operating leverage on higher volumes
Risk Factors
- Prolonged hospital budget constraints
- Regulatory enforcement delays or rollbacks
- Execution missteps in scaling production or service delivery
Key Debates
P/E multiple expands to 25x by Q4 as 8.8% growth holds
Gross margin expands to 45.5% by H1 2025, boosting EPS
ROE surpasses 11% by Q3 2025, justifying P/B re-rating